Publication

Wel prostaatkanker, maar niet actief behandelen

Blanker, M. H. & Bangma, C. H., 31-Aug-2019, In : Nederlands Tijdschrift voor Geneeskunde. 163, 26-27, 4 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Blanker, M. H., & Bangma, C. H. (2019). Wel prostaatkanker, maar niet actief behandelen. Nederlands Tijdschrift voor Geneeskunde, 163(26-27).

Author

Blanker, Marco H. ; Bangma, Chris H. / Wel prostaatkanker, maar niet actief behandelen. In: Nederlands Tijdschrift voor Geneeskunde. 2019 ; Vol. 163, No. 26-27.

Harvard

Blanker, MH & Bangma, CH 2019, 'Wel prostaatkanker, maar niet actief behandelen', Nederlands Tijdschrift voor Geneeskunde, vol. 163, no. 26-27.

Standard

Wel prostaatkanker, maar niet actief behandelen. / Blanker, Marco H.; Bangma, Chris H.

In: Nederlands Tijdschrift voor Geneeskunde, Vol. 163, No. 26-27, 31.08.2019.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Blanker MH, Bangma CH. Wel prostaatkanker, maar niet actief behandelen. Nederlands Tijdschrift voor Geneeskunde. 2019 Aug 31;163(26-27).


BibTeX

@article{d36a876d64f14276ac29e7d4cd8aa21f,
title = "Wel prostaatkanker, maar niet actief behandelen",
abstract = "Prostate cancer is the most common cancer in men. Because these tumours are usually detected by early diagnosis, prostate cancer is often limited to the prostate when diagnosed. Withholding active treatment, with active surveillance or watchful waiting are full options for men with this diagnosis. In active surveillance, men receive a structured follow-up with repeated determinations of the prostate-specific antigen (PSA) and prostate biopsies, often supported by MRI. When the tumour develops, active treatment can still be initiated. With this approach, the 10-year survival rate is high and a significant proportion of men remain untreated. With watchful waiting no structural monitoring takes place; instead one waits until the prostate cancer becomes symptomatic. This mainly concerns bone pain due to metastasis and obstruction of the urethra due to local growth. Explanation about these options is essential and GPs can play an important role in this.",
keywords = "prostate specific antigen, article, cancer therapy, Gleason score, human, prostate cancer",
author = "Blanker, {Marco H.} and Bangma, {Chris H.}",
year = "2019",
month = "8",
day = "31",
language = "Dutch",
volume = "163",
journal = "Ned Tijdschr Geneeskd",
issn = "0028-2162",
publisher = "NLM (Medline)",
number = "26-27",

}

RIS

TY - JOUR

T1 - Wel prostaatkanker, maar niet actief behandelen

AU - Blanker, Marco H.

AU - Bangma, Chris H.

PY - 2019/8/31

Y1 - 2019/8/31

N2 - Prostate cancer is the most common cancer in men. Because these tumours are usually detected by early diagnosis, prostate cancer is often limited to the prostate when diagnosed. Withholding active treatment, with active surveillance or watchful waiting are full options for men with this diagnosis. In active surveillance, men receive a structured follow-up with repeated determinations of the prostate-specific antigen (PSA) and prostate biopsies, often supported by MRI. When the tumour develops, active treatment can still be initiated. With this approach, the 10-year survival rate is high and a significant proportion of men remain untreated. With watchful waiting no structural monitoring takes place; instead one waits until the prostate cancer becomes symptomatic. This mainly concerns bone pain due to metastasis and obstruction of the urethra due to local growth. Explanation about these options is essential and GPs can play an important role in this.

AB - Prostate cancer is the most common cancer in men. Because these tumours are usually detected by early diagnosis, prostate cancer is often limited to the prostate when diagnosed. Withholding active treatment, with active surveillance or watchful waiting are full options for men with this diagnosis. In active surveillance, men receive a structured follow-up with repeated determinations of the prostate-specific antigen (PSA) and prostate biopsies, often supported by MRI. When the tumour develops, active treatment can still be initiated. With this approach, the 10-year survival rate is high and a significant proportion of men remain untreated. With watchful waiting no structural monitoring takes place; instead one waits until the prostate cancer becomes symptomatic. This mainly concerns bone pain due to metastasis and obstruction of the urethra due to local growth. Explanation about these options is essential and GPs can play an important role in this.

KW - prostate specific antigen

KW - article

KW - cancer therapy

KW - Gleason score

KW - human

KW - prostate cancer

M3 - Article

VL - 163

JO - Ned Tijdschr Geneeskd

JF - Ned Tijdschr Geneeskd

SN - 0028-2162

IS - 26-27

ER -

ID: 91011298